https://pharmadevicenews.com/evorpacept-biomarker-signal-deepens-in-her2-positive-gastric-cancer-as-alx-oncology-shifts-focus/ PharmaDeviceNews en 2026-09-28T22:19:56+00:00 Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus ALX Oncology, evorpacept, HER2, Nature Medicine https://pharmadevicenews.com/wp-content/uploads/2026/09/Gastric-cancer-imaging-e1790632883220.webp https://pharmadevicenews.com/teva-wins-fda-approval-for-degevma-biosimilar-across-all-xgeva-indications/ PharmaDeviceNews en 2026-09-28T20:53:58+00:00 Teva wins FDA approval for DEGEVMA biosimilar across all Xgeva indications Amgen, DEGEVMA, Teva Pharmaceutical Industries, XGEVA https://pharmadevicenews.com/wp-content/uploads/2026/09/Study-of-cancer-related-bone-disease-e1790628511988.webp https://pharmadevicenews.com/one-carvykti-infusion-five-years-without-maintenance-johnson-johnsons-tiny-trial-delivers-a-striking-myeloma-signal/ PharmaDeviceNews en 2026-09-28T06:42:41+00:00 One Carvykti infusion, five years without maintenance: Johnson & Johnson’s tiny trial delivers a striking myeloma signal CARVYKTI, Johnson & Johnson, Legend Biotech Corporation https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-28-2026-12_10_54-PM-e1790577701308.webp